PubMed

Nature communications 2018 06 199(1) 2404 doi 10.1038/s41467-018-04495-z Abstract A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine prostate cancer is an uncommon and aggressive...

The New England journal of medicine 2018 06 13378(25) e34 doi 10.1056/NEJMoa1800389 Abstract BACKGROUND Observational cohort studies and a secondary prevention trial have shown inverse associations between adherence to the...

International journal of molecular sciences 2018 06 0619(6) pii 10.3390/ijms19061689 Abstract Parkinson’s disease (PD) is a progressively debilitating neurodegenerative disease characterized by α-synucleinopathy,...

Nature communications 2018 06 089(1) 2231 doi 10.1038/s41467-018-04651-5 Abstract CRISPR advances genome engineering by directing endonuclease sequence specificity with a guide RNA molecule (gRNA). For precisely targeting a gene...

Frontiers in oncology 2018 05 248() 161 doi 10.3389/fonc.2018.00161 Abstract Advances in chemotherapy and targeted therapies have improved survival in cancer patients with an increase of the incidence of newly diagnosed brain...

Frontiers in aging neuroscience 2018 04 1710() 109 doi 10.3389/fnagi.2018.00109 Abstract It has been 200 years since Parkinson disease (PD) was described by Dr. Parkinson in 1817. The disease is the second most common...

The New England journal of medicine 2018 04 16() doi 10.1056/NEJMoa1801005 Abstract Background First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy....

The New England journal of medicine 2018 04 16() doi 10.1056/NEJMoa1716078 Abstract Background Antibodies that block programmed death 1 (PD-1) protein improve survival in patients with advanced non-small-cell lung cancer (NSCLC)...